Home >> Tag Archives: Dako

Tag Archives: Dako

Dako and Amgen expand collaboration, 6/15

June 2015—Dako, an Agilent Technologies Company, announced a new master collaboration agreement with Amgen. The expanded collaboration will allow both companies to benefit from knowledge sharing within the field of drug-diagnostic research and development and in relation to companion diagnostic products.

Read More »

EU launch of HER2 ISH assay, 11/14

November 2014—Dako, an Agilent Technologies company, announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis. The assay will enable pathology laboratories to integrate the Dako HER2 IQFISH and IQFISH hybridization buffer into their immunohistochemistry workflow.

Read More »

Dako and Merck to collaborate, 7/14

July 2014—Dako and Merck & Co. will collaborate to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this collaboration will be evaluated as part of the clinical development program from Merck’s investigational anti-PD-1 antibody being studied for the treatment of cancer.

Read More »

Bone marrow tissue stain, 5/14

May 2014—Dako added the Jenner-Wright Giemsa stain to its Artisan Link portfolio of automated stains. The stain is designed to provide clear differentiation and detail of the hematopoietic cells in bone marrow tissue samples for the diagnosis of cancer, aplastic anemia, and myelofibrosis.

Read More »

IHC guidebook, 3/14

March 2014—The sixth edition of The Educational Guidebook: IHC Staining Methods, published by Dako, is now available. The guidebook is used as a teaching and learning tool worldwide and serves as a reference for ensuring correct staining processes within the lab. Several experts within the field of IHC wrote this new edition and Clive R. Taylor, MD, is the editor.

Read More »

Antibody to aid in diagnosing breast cancer, 5/13:87

Dako has received FDA clearance to sell its Flex monoclonal rabbit anti-human estrogen receptor alpha, clone EP1 in the United States. The clone has been available in Europe for some time. With this diagnostic tool, breast cancer patients can be confident they are receiving effective treatment for their particular type of breast cancer.

Read More »

Staining platform, 4/13:84

Dako’s Omnis solution, a new addition to the company’s immunohistochemistry portfolio, consists of hardware, software, and reagents. It automates IHC and ISH processes, allowing entire patient cases to be processed simultaneously. The solution offers continuous loading, batch loading, and overnight run options. Its state-of-the-art software allows slide processing and instrument maintenance to be traced to individual operators, greatly increasing quality control.

Read More »

Dako, Lilly to collaborate, 3/13:76

Dako, an Agilent Technologies company, has entered into a master framework agreement with Eli Lilly and Company for the development of companion diagnostic tests to identify patients who may be more likely to benefit from an investigational oncology medicine currently under development by Lilly.

Read More »

FISH assay, 3/13:72

Dako recently introduced in the United States its instant quality in situ hybridization, or IQISH, technology, which will reduce the turnaround time for cancer evaluation from two days to three and a half hours. HER2 IQFISH PharmDx, a fluorescence in situ hybridization assay, is the first product approved by the FDA that uses IQISH technology, which is based on the company’s fast IQISH hybridization buffer chemistry.

Read More »
CAP TODAY
X